Statements (21)
| Predicate | Object |
|---|---|
| gptkbp:instanceOf |
gptkb:biotechnology
|
| gptkbp:CEO |
gptkb:Mark_DePristo
|
| gptkbp:focusesOn |
gptkb:machine_learning
antibody engineering |
| gptkbp:foundedYear |
2019
|
| gptkbp:founder |
gptkb:Mark_DePristo
gptkb:Trevor_Martin |
| gptkbp:fundedBy |
gptkb:Series_B
|
| gptkbp:headquartersLocation |
gptkb:San_Mateo,_California,_United_States
|
| https://www.w3.org/2000/01/rdf-schema#label |
BigHat Biosciences
|
| gptkbp:industry |
gptkb:biotechnology
|
| gptkbp:investor |
gptkb:Andreessen_Horowitz
gptkb:8VC gptkb:Amgen_Ventures Section 32 |
| gptkbp:mission |
improving antibody discovery and development using AI and wet lab integration
|
| gptkbp:technology |
gptkb:artificial_intelligence
synthetic biology |
| gptkbp:website |
https://www.bighatbio.com/
|
| gptkbp:bfsParent |
gptkb:a16z_Bio
|
| gptkbp:bfsLayer |
7
|